Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer
- PMID: 38839260
- DOI: 10.1177/10668969241256109
Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer
Abstract
Introduction. MYC overexpression is a known phenomenon in breast cancer. This study investigates the correlation of MYC gene copy number amplification and MYC protein overexpression with coexisting genetic abnormalities and associated clinicopathologic features in breast cancer patients. Methods. The study analyzed data from 81 patients with localized or metastatic breast cancers using targeted next-generation sequencing and MYC immunohistochemical studies, along with pathological and clinical data. Results. Applying the criteria of MYC/chromosome 8 ratio ≥5, MYC copy number amplified tumors (n = 11, 14%) were associated with invasive ductal carcinoma (91% vs 68%, P = .048), poorly differentiated (grade 3, 64% vs 30%, P = .032), mitotically active (Nottingham mitotic score 3, 71% vs 20%, P = .004), estrogen receptor (ER)-negative (45% vs 12%, P = .008), and triple-negative (56% vs 12%, P = .013) compared to MYC non-amplified tumors. Among MYC-amplified breast cancer patients, those with triple-negative status showed significantly shorter disease-free survival time than non-triple negative MYC-amplified patients (median survival month: 25.5 vs 127.6, P = .049). MYC amplification is significantly associated with TP53 mutation (P = .007). The majority (10 of 11; 91%) of MYC-amplified tumors showed positive c-MYC immunostaining. Conclusion. Breast cancers with MYC copy number amplication display distinct clinicopathologic characteristics indicative of more aggressive behavior.
Keywords: MYC; breast cancer; copy number amplification.
Conflict of interest statement
Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
Characteristics of MYC Amplification and Their Association with Clinicopathological and Molecular Factors in Patients with Breast Cancer.DNA Cell Biol. 2022 May;41(5):521-538. doi: 10.1089/dna.2020.6487. Epub 2022 Apr 26. DNA Cell Biol. 2022. PMID: 35475703
-
MYC amplification in subtypes of breast cancers in African American women.BMC Cancer. 2018 Mar 9;18(1):274. doi: 10.1186/s12885-018-4171-6. BMC Cancer. 2018. PMID: 29523126 Free PMC article.
-
Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes.Mod Pathol. 2010 Jul;23(7):1029-39. doi: 10.1038/modpathol.2010.84. Epub 2010 May 14. Mod Pathol. 2010. PMID: 20473280
-
Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses.Br J Cancer. 2004 Apr 19;90(8):1612-9. doi: 10.1038/sj.bjc.6601703. Br J Cancer. 2004. PMID: 15083194 Free PMC article.
-
Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. doi: 10.5507/bp.2009.002. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009. PMID: 19365520 Review.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous